枝孢
医学
安慰剂
过敏
哮喘
激发试验
内科学
免疫疗法
养生
免疫学
生物
病理
微生物学
曲霉
替代医学
癌症
作者
H.V. Malling,Sten Dreborg,B. Weeke
出处
期刊:Allergy
[Wiley]
日期:1986-09-01
卷期号:41 (7): 507-519
被引量:127
标识
DOI:10.1111/j.1398-9995.1986.tb00336.x
摘要
A placebo‐controlled, double‐blind study of immunotherapy with the mould species Cladosporium was performed in 22 adult asthmatics. The diagnosis of Cladosporium allergy was based on a combination of bronchial provocation test and daily symptom score in the Cladosporium season. An aqueous preparation of a potent, biologically standardized and purified extract was used in a clustered dose‐increase regimen. The clinical efficacy was evaluated by a combination of symptoms (asthma score + peak flow) and consumption of antiasthmatic medication. The mean changes in symptoms and medication consumption over a 10–week registration period (peak Cladosporium season) in 1982 after 5–7 months of immunotherapy were compared with the corresponding 1981 pretreatment 10‐week period A significant ( P = 0.03) difference in terms of “improved”, “unchanged” and “deteriorated” patients in favour of Cladosporium treatment was found. Approximately 80% in the Cladosporium group showed improved/unchanged symptoms contrary to 30% of the placebo treated. Side effects were observed frequently but only in the Cladosporium ‐treated. About 70% experienced a large local reaction and 100% had episodes of asthma during dose‐increase phase. Only a few severe systemic reactions occurred. Based on the clinical efficacy of the treatment we consider immunotherapy with Cladosporium feasible for highly specialized clinics.
科研通智能强力驱动
Strongly Powered by AbleSci AI